Previous 10 | Next 10 |
This is a recap of DCVax-L's pedigree. Stock is down 25% since my last neutral article. I am celebrating NWBO's one-year data lock anniversary with a buy. For further details see: Northwest Bio: Nowhere To Go But Up
NWBO's DCVax-L trial is being unblinded. The company is not presenting at ASCO. I expect this to close before year end. For further details see: Northwest Biotherapeutics: CEO Says Unblinding Is A Work In Progress
Interest in Northwest Bio (NWBO) has increased in recent days as some investors feel that the company is poised to release strong phase 3 data on its brain cancer treatment -- perhaps as soon as next month's American Society of Clinical Oncology ("ASCO") annual meeting.The double-blind, place...
UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO) UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO) Application Submitted to MHRA for Certification of Sawston Facility P...
Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility Application for MHRA Regulatory Certification of Facility In Preparation PR Newswire BETHESDA, Md. , March 16, 2021 /PRNewswire/ -- Northwes...
NWBO has finally arrived at its endgame, and it must announce either positive or negative pivotal data very soon, no later than 2021. The company has managed to secure some funding. The wait may finally be over for long-term holders of this battleground stock. For further de...
FN Media Group Presents USA News Group News Commentary Vancouver, BC – February 24, 2021 – USA News Group – The way we think about treating brain cancers is being quietly revolutionized, buried beneath recent headline-grabbing announcements...
Penny Stocks To Watch After The Holidays Investors are finding penny stocks to watch as markets heat up into the end of 2020. With the pandemic in mind and a new president on the horizon, 2021 could have a lot of potential for different sectors and industries. But, investors should ...
NWBO has run an 18-year long trial in GBM, one of the deadliest of cancers. It has been mired in controversies, and it has no cash. Its trial data has been locked, and will be blinded, hopefully in a short while. For further details see: Northwest Biotherapeutics: Blinde...
Robinhood Penny Stocks To Watch Next Week In December 2020, there are plenty of options when it comes to penny stocks to watch . While these cheap stocks are quite volatile, there are ways that traders can use this volatility to their advantage. One of the best ways to start finding...
News, Short Squeeze, Breakout and More Instantly...
Northwest Biotherapeutics Inc. Company Name:
NWBO Stock Symbol:
OTCMKTS Market:
Northwest Biotherapeutics Inc. Website:
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities PR Newswire Over 77% Of All Shares Voted; Proposals Received Overwhelming Positive Votes BETHESDA, Md. , July 3, 2024 /PRNewswire/ -- No...
Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property PR Newswire Complementary to Technology & IP Already Owned or In-Licensed; Significant Step in Building a Leading Dendritic Cell Franchise ...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...